Skip to main content
. 2021 Feb 9;26(4):e715–e718. doi: 10.1002/onco.13694

Figure 1.

Figure 1

Frequency (percentage of patients) of each listed alteration in prostate cancer. (A): Cyclin pathway gene alterations in patients with prostate cancer alterations in (B). Alterations in putative cyclin resistance genes (RB1 and CCNE1) and AR Abbreviations: adeno, adenocarcinoma; AR, androgen receptor; NE, neuroendocrine.